|
CANTATA EvaluatorSM for AVII |
|||||||
|---|---|---|---|---|---|---|---|
|
© 2024 BreakoutWatch.com |
New CE:
|
||||||
| Company Information | |||||||
| Symbol: | AVII | ||||||
| Company: | AVI BioPharma, Inc. | ||||||
| Company Description: | AVI BioPharma, Inc. (AVI) is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of both rare and infectious diseases. The Company is primarily focused on rapidly advancing the development of its disease-modifying Duchenne muscular dystrophy drug candidates with the intent to realize the product opportunities of such candidates and provide clinical benefits. It is also focused on developing therapeutics for the treatment of infectious diseases. The Company�s lead program focuses on the development of disease modifying therapeutic candidates for Duchenne muscular dystrophy (DMD), a rare genetic muscle wasting disease caused by the absence of dystrophin, a protein necessary for muscle function. AVI-4658 is its lead therapeutic candidate for DMD and is intended to target a substantial group of individuals with DMD. | ||||||
| Stock is Optionable: | No | ||||||
| SEC Filings | Edgar Online | ||||||
| General Due Diligence and Earnings Date Info: | Due Diligence | ||||||
| Exchange: | NASDAQ | ||||||
| CANTATA Evaluation for 11/21/2024 | |||||||
| CE Zone |
Time- liness | CET | CEF | CE* | Industry | Industry Rank |
Industry Score |
| - | 0/2 | / 7 | 0 / 11 | 0 /18 | / 215 | / 100 | |
*Excluding Timeliness
points |
|||||||
| Timeliness | |||||||
| Item | Data | Points | Maximum Possible |
||||
| 1 | Currently listed on CwH,
DB, HTF or SQZ watchlists
|
0 | 1 | ||||
| 2 | Broke out in last 5 days
and within 5% of BoP |
0 | 1 | ||||
Total Timeliness Points |
0 | 2 | |||||
| CANTATA Evaluation Technical (CET) | |||||||||||||
| Item | Data | Points | Maximum Possible |
||||||||||
| 1 | Price relative to 50 and 200 day moving averages; 50 day relative to 200 day moving average
|
0.00 | 3 | ||||||||||
| 2 | Relative Strength Rank
|
0.00 | 3 | ||||||||||
| 3 | Rank in Industry
|
0.00 | 1 | ||||||||||
| 4 | Price relative to 52 week high
|
0.00 | 1 | ||||||||||
| 5 | Up/Down Ratio
|
0.00 | 1 | ||||||||||
Miscellaneous Technical Data (no points assigned)
|
n/a | n/a | |||||||||||
| Total Technical Points (CET) | 0.00 | 9 | |||||||||||
| CANTATA Evaluation Fundamentals (CEF) | |||||||
| We do not have any fundamental data in our database for AVII | |||||||
| Total Fundamental Points (CEF) | 0.00 | 11 | |||||
| Total CANTATA Evaluation Points | 0.00 | 20 | |||||